GLP Watchdog

GoodRx vs Noom

Neither GoodRx nor Noom has an FDA warning letter on record. On brand-name tirzepatide pen, GoodRx costs $600 less a year at standing rates: $299 a month against $349 a month at Noom.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

GoodRx / Noom

GoodRx logo

GoodRx

7.8/10

Noom logo

Noom

5.8/10

FDA warning letters
None on record
None on record
Pharmacy
Brand-name only; no compounding
None named in our record
Lowest standing price
$149/moFoundayo (orforglipron) pill
$179/moCompounded semaglutide injection
States
48 states
No state list published
Checked
Prices captured Record checked October 2026
Prices captured Record checked October 2026
Visit GoodRx
Visit Noom

Neither GoodRx nor Noom pays us. Links to them earn nothing. Scores: GoodRx 7.8, Noom 5.8. How we are paid

What the record shows

  1. 01

    Neither GoodRx nor Noom has an FDA warning letter on record.

  2. 02

    Noom names no compounding pharmacy in our record. GoodRx sells brand-name medication only.

  3. 03

    On brand-name tirzepatide pen, GoodRx costs $600 less a year at standing rates: $299 a month against $349 a month at Noom.

  4. 04

    Only GoodRx lists a price for Foundayo (orforglipron) pill. Only Noom lists a price for compounded semaglutide injection.

  5. 05

    GoodRx lists 48 states. Noom publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

GoodRx

Noom

Brand-name tirzepatide pen

$299/moLower

$3,588 a year

$349/mo

$4,188 a year

Compounded semaglutide injection
Not sold or not priced

$179/mo

$2,148 a year

Foundayo (orforglipron) pill

$149/mo

$1,788 a year

Not sold or not priced
Price includes
Not stated
Clinician visits, coaching
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
Not stated
Refunds
Services and medication are generally non-refundable
Refunds only before a prescription is written; renewal charges are not refunded

Read off each seller’s own pages. GoodRx: October 30, 2026. Noom: October 30, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for GoodRx

7.8/10
  • $600 a year less on brand-name tirzepatide pen
  • Sells Foundayo (orforglipron) pill, which Noom does not price
Visit GoodRx

The case for Noom

5.8/10
  • Sells compounded semaglutide injection, which GoodRx does not price
  • Names no compounding pharmacy
  • Publishes no state list
Visit Noom

Scores

GoodRx 7.8 · Noom 5.8 out of 10. Six weighted parts.

Value25%

8.7A
vs
B
0.9

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

5.0A
vs
B
8.0

Trust & Safety15%

6.0A
vs
B
6.5

Accessibility10%

9.7A
vs
B
5.0

Support10%

5.0A
vs
B
4.0

The score is the same formula for every seller. Payment does not enter it. Method

GoodRx vs Noom: questions

Neither GoodRx nor Noom has an FDA warning letter on record. Letters are matched to a seller by company, domain and address, never by a similar name.
Noom names no compounding pharmacy in our record. GoodRx sells brand-name medication only.
GoodRx, by $600 a year at standing rates. GoodRx: $299 a month, about $3,588 a year. Noom: $349 a month, about $4,188 a year.
GoodRx states you can cancel at any time; refunds: services and medication are generally non-refundable. Noom states you can cancel at any time; refunds: refunds only before a prescription is written; renewal charges are not refunded.
Neither GoodRx nor Noom pays us. Links to them earn nothing. Scores: GoodRx 7.8, Noom 5.8.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks